While lowering its target price from €127 to €120, Invest Securities reiterates its 'buy' opinion on bioMérieux, 'an unfairly discounted stock in the IVD (in vitro diagnostics) industry, given its remarkable ability to navigate the post-Covid environment'.

In 2023, the Group continues to outperform its peers, with another excellent organic performance", believes the analyst, for whom the market's neutral reaction to the annual results can be explained by mixed 2024 targets.

"Despite the disappointment over the margin target, we find this publication satisfactory overall, as it shows remarkable resilience in growth, with numerous growth levers clearly identified and outperforming", he continues.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.